Mazdutide — SEO Product Content

SEO Title

Mazdutide Peptide | GLP-1 & Glucagon Dual Agonist Research

SEO Meta Description

Mazdutide research peptide for studies of GLP-1 and glucagon receptor signaling, obesity biology, glucose metabolism, energy balance, liver fat and metabolic research.

Suggested URL Slug

/product/mazdutide/

SEO Product Description

Mazdutide Research Peptide

Mazdutide (IBI362) is a long-acting dual glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonist investigated extensively in obesity, diabetes and metabolic research.

By simultaneously activating GLP-1 and glucagon receptors, Mazdutide provides a research model for examining the interaction between incretin signaling, glucagon biology, appetite regulation, glucose metabolism, energy expenditure, body weight and hepatic metabolism.

Clinical development has advanced significantly. Mazdutide received its first approval in China in June 2025 for long-term body-weight management in eligible adults with overweight or obesity, followed by approval in September 2025 for glycemic control in adults with type 2 diabetes.

Pure Axis Peptides offers Mazdutide as a research-use peptide for qualified laboratory and scientific investigations.

What Is Mazdutide?

Mazdutide is an investigational long-acting peptide designed to activate two metabolically important receptors:

GLP-1 receptor + Glucagon receptor

It is also known by the development code IBI362.

The dual mechanism distinguishes Mazdutide from selective GLP-1 receptor agonists such as semaglutide.

GLP-1 receptor activation is associated with pathways involved in:

• Glucose-dependent insulin secretion
• Appetite regulation
• Satiety
• Gastrointestinal signaling
• Glucose homeostasis

Glucagon receptor activation influences:

• Hepatic glucose metabolism
• Lipid metabolism
• Energy expenditure
• Substrate utilization
• Metabolic homeostasis

Together, these pathways make Mazdutide highly relevant to metabolic research.

Mazdutide and GLP-1 Receptor Signaling

The GLP-1 receptor (GLP-1R) is a G-protein-coupled receptor involved in glucose and energy regulation.

Activation of GLP-1R can influence:

• Insulin secretion
• Appetite
• Satiety
• Gastric emptying
• Glucose metabolism
• Pancreatic signaling

Mazdutide incorporates GLP-1 receptor agonism into a broader dual-receptor mechanism.

Researchers can therefore use Mazdutide to investigate GLP-1 signaling alongside simultaneous glucagon receptor activation.

Mazdutide and Glucagon Receptor Signaling

The glucagon receptor (GCGR) is particularly important in hepatic metabolism.

Glucagon signaling can influence:

• Glycogen breakdown
• Hepatic glucose production
• Fat oxidation
• Energy expenditure
• Lipid metabolism
• Amino-acid metabolism

Mazdutide’s GCGR activity provides an important mechanistic distinction from selective GLP-1 receptor agonists.

This makes the compound useful for investigating how glucagon signaling interacts with incretin pathways.

Mazdutide and Dual Agonism

The central pharmacological feature of Mazdutide is dual GLP-1R/GCGR agonism.

The research model can be represented as:

Mazdutide → GLP-1R + GCGR → metabolic signaling → changes in energy balance and glucose/lipid metabolism

This dual activity has generated interest in:

• Obesity research
• Diabetes research
• Energy expenditure
• Glucose metabolism
• Liver metabolism
• Body-composition research
• Metabolic disease

Mazdutide belongs to the broader class of multi-receptor metabolic peptides.

Mazdutide and Obesity Research

Obesity is one of the primary areas of Mazdutide research.

A Phase 3 randomized trial in Chinese adults with overweight or obesity evaluated once-weekly 4 mg and 6 mg Mazdutide over 48 weeks. The study found significantly greater weight reduction with Mazdutide than placebo.

A later Phase 1 high-dose study investigated doses up to 16 mg and reported substantial body-weight reductions at week 20, providing additional data on higher-dose exposure.

Research endpoints can include:

• Percentage body-weight change
• Body-mass index
• Waist circumference
• Fat mass
• Lean mass
• Appetite
• Glycemic parameters
• Metabolic biomarkers

Mazdutide and Body-Weight Research

Clinical studies have demonstrated significant reductions in body weight with once-weekly Mazdutide.

In the Phase 3 trial of Chinese adults with overweight or obesity, both 4 mg and 6 mg doses produced significantly greater weight loss than placebo at 48 weeks.

These findings make Mazdutide body-weight research and Mazdutide obesity research strong secondary SEO themes.

The page should nevertheless distinguish clinical trial outcomes from the characteristics of research-grade material.

Mazdutide and Energy Expenditure

Glucagon receptor activation is associated with increased metabolic activity and changes in energy substrate utilization.

This makes Mazdutide useful for research into:

• Energy expenditure
• Fat oxidation
• Substrate utilization
• Hepatic metabolism
• Energy balance
• Metabolic adaptation

The combination of GLP-1 and glucagon receptor signaling is one reason dual agonists have attracted significant interest in obesity research.

Mazdutide and Appetite Research

GLP-1 signaling plays an important role in appetite and satiety pathways.

Mazdutide research can therefore investigate:

• Food intake
• Satiety
• Appetite regulation
• Energy balance
• Central metabolic signaling
• Body-weight regulation

The dual mechanism also allows researchers to investigate how appetite-related GLP-1 signaling interacts with glucagon-mediated metabolic effects.

Mazdutide and Glucose Metabolism

Mazdutide has been studied extensively in relation to glycemic regulation.

GLP-1 receptor activation can enhance glucose-dependent insulin secretion, while glucagon receptor signaling influences hepatic glucose production.

This creates a useful experimental system for investigating:

• Blood glucose
• Insulin secretion
• Glycemic control
• Hepatic glucose production
• Insulin sensitivity
• Glucose homeostasis

Mazdutide received approval in China in 2025 for glycemic control in adults with type 2 diabetes.

Mazdutide and Type 2 Diabetes Research

Type 2 diabetes is an important clinical research area for Mazdutide.

The compound’s dual GLP-1R/GCGR mechanism provides a different approach from selective GLP-1 receptor agonists.

Research can investigate relationships between:

• Body weight
• Glycated hemoglobin
• Fasting glucose
• Insulin sensitivity
• Glucagon signaling
• Energy metabolism

Mazdutide is therefore relevant to both diabetes research and broader metabolic physiology.

Mazdutide and Liver Metabolism

The liver is a major target of glucagon signaling.

Because Mazdutide activates the glucagon receptor, hepatic metabolism is an important research area.

Researchers can investigate:

• Hepatic glucose production
• Fatty-acid oxidation
• Lipid metabolism
• Liver energy metabolism
• Hepatic steatosis
• Metabolic signaling

This provides a mechanistic connection between Mazdutide and metabolic liver research.

Mazdutide and Liver Fat

Excess liver fat is closely associated with obesity and metabolic dysfunction.

The dual GLP-1/glucagon mechanism has generated interest in whether Mazdutide can influence hepatic fat accumulation.

Mazdutide has been evaluated in clinical development programs involving metabolic dysfunction-associated fatty liver disease, alongside its obesity and diabetes programs.

This makes Mazdutide liver-fat research a useful long-tail SEO topic.

Mazdutide and MASLD Research

Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excess liver fat associated with metabolic dysfunction.

Mazdutide is being investigated in metabolic liver disease because both GLP-1 and glucagon pathways can influence systemic and hepatic metabolism.

Potential research endpoints include:

• Liver fat
• Hepatic steatosis
• Body weight
• Insulin resistance
• Metabolic biomarkers
• Liver enzymes
• Fibrosis-related measures

Mazdutide’s clinical development has included evaluation for metabolic dysfunction-associated fatty liver disease.

Mazdutide and MASH Research

Metabolic dysfunction-associated steatohepatitis (MASH) represents a more advanced form of metabolic liver disease.

Research into dual GLP-1/glucagon agonists has examined whether improvements in weight and hepatic metabolism can translate into improvements in steatohepatitis and liver pathology.

For SEO, terms such as Mazdutide MASH research, Mazdutide liver research, and Mazdutide MASLD research can support a broader metabolic-liver content cluster.

Mazdutide and Lipid Metabolism

Glucagon signaling can influence lipid utilization and hepatic fat metabolism.

Mazdutide therefore provides an experimental model for investigating:

• Fat oxidation
• Hepatic lipid metabolism
• Triglyceride metabolism
• Fatty-acid utilization
• Adipose-tissue metabolism
• Energy substrate selection

These mechanisms may help explain the interest in Mazdutide for both obesity and metabolic liver disease research.

Mazdutide and Body Composition

Total body weight is only one component of body composition.

Researchers can also investigate how Mazdutide influences:

• Fat mass
• Lean mass
• Visceral adipose tissue
• Waist circumference
• Body-fat percentage
• Liver fat

Body-composition analysis can provide additional information about how dual metabolic receptor activation changes tissue-level energy storage.

Mazdutide and Cardiometabolic Research

Obesity and type 2 diabetes are associated with a broad range of cardiometabolic risk factors.

Mazdutide research can therefore include:

• Blood pressure
• Lipid profiles
• Glycemic control
• Body weight
• Waist circumference
• Metabolic biomarkers
• Cardiometabolic risk

These endpoints provide a broader context for understanding the biological effects of GLP-1/glucagon dual agonism.

Mazdutide vs. Semaglutide

Mazdutide and semaglutide share GLP-1 receptor activity but differ in receptor profile.

Mazdutide

• GLP-1 receptor agonist
• Glucagon receptor agonist
• Dual agonist
• Investigated in obesity and type 2 diabetes
• Also investigated in metabolic liver disease

Semaglutide

• Selective GLP-1 receptor agonist
• Extensive clinical development
• Established applications in diabetes and obesity

A Phase 3 study has been designed to directly compare Mazdutide with semaglutide in Chinese adults with type 2 diabetes and obesity.

Explore Semaglutide for related GLP-1 receptor research.

Mazdutide vs. Tirzepatide

Mazdutide and tirzepatide are both multi-receptor metabolic peptides, but they activate different receptor combinations.

Mazdutide: GLP-1R + GCGR.

Tirzepatide: GLP-1R + GIPR.

This makes them useful comparative models for investigating how different combinations of metabolic hormone receptors affect:

• Appetite
• Body weight
• Glucose metabolism
• Energy balance
• Lipid metabolism

Explore Tirzepatide for GLP-1/GIP dual-agonist research.

Mazdutide vs. Survodutide

Mazdutide and survodutide are especially close mechanistic comparators because both are GLP-1/glucagon receptor dual agonists.

Both compounds have been investigated for:

• Obesity
• Body-weight reduction
• Glucose metabolism
• Energy balance
• Metabolic liver disease

This makes a Mazdutide vs. Survodutide comparison page an excellent supporting SEO asset.

Explore Survodutide for related dual GLP-1/glucagon research.

Mazdutide vs. Retatrutide

Mazdutide and retatrutide both involve glucagon receptor and GLP-1 receptor activity.

The key difference is that retatrutide additionally activates the GIP receptor.

Mazdutide: GLP-1R + GCGR.

Retatrutide: GLP-1R + GIPR + GCGR.

This creates a useful research comparison between dual- and triple-receptor metabolic agonism.

Explore Retatrutide for triple-agonist metabolic research.

Mazdutide vs. Cagrilintide

Cagrilintide works through the amylin pathway, making it mechanistically distinct from Mazdutide.

Comparing the compounds can help researchers examine differences between:

• GLP-1/glucagon signaling
• Amylin signaling
• Appetite regulation
• Energy balance
• Metabolic physiology

Explore Cagrilintide for amylin-pathway research.

Mazdutide Research Applications

Mazdutide may be relevant to laboratory studies involving:

GLP-1 Research: Investigating GLP-1 receptor activation.

Glucagon Research: Studying glucagon receptor signaling.

Dual Agonist Research: Examining simultaneous GLP-1R/GCGR activation.

Obesity Research: Investigating body-weight regulation and energy balance.

Diabetes Research: Studying glucose homeostasis and metabolic signaling.

Energy Metabolism: Investigating energy expenditure and substrate utilization.

Liver Research: Studying hepatic metabolism and liver fat.

MASLD Research: Investigating metabolic liver disease.

MASH Research: Studying steatohepatitis and fibrosis-related mechanisms.

Lipid Research: Investigating fatty-acid and triglyceride metabolism.

Body Composition Research: Studying fat mass, lean mass and visceral adiposity.

Cardiometabolic Research: Investigating metabolic risk factors.

Peptide Pharmacology: Studying multi-receptor metabolic agonism.

Mazdutide Research Material

Researchers should verify the current Pure Axis Peptides product specification, peptide identity, sequence, purity, formulation, storage requirements and batch-specific certificate of analysis (COA) before laboratory use.

Mazdutide is a pharmacologically active metabolic peptide. Appropriate laboratory handling procedures and applicable institutional requirements should be followed.

Approved Pharmaceutical vs. Research Material

Mazdutide has an important regulatory distinction that should be made clear on the product page.

In China, Mazdutide received its first approval in June 2025 for long-term weight management in eligible adults with overweight or obesity. It subsequently received approval for glycemic control in adults with type 2 diabetes.

Those approvals apply to the approved pharmaceutical product, formulation, manufacturing standards, dosing instructions and labeled indications.

A research-grade Mazdutide product supplied by Pure Axis should not be represented as an equivalent pharmaceutical product or as approved for human use.

Explore Related Research

Mazdutide belongs within a strong GLP-1 / glucagon / metabolic peptide research cluster.

Explore Semaglutide for selective GLP-1 receptor research.

Explore Tirzepatide for GLP-1/GIP dual-agonist research.

Explore Survodutide for GLP-1/glucagon dual-agonist research.

Explore Retatrutide for GLP-1/GIP/glucagon triple-agonist research.

Explore Cagrilintide for amylin-pathway research.

Browse the Peptides collection for additional peptide research materials.

Visit Shop All Products for the complete Pure Axis Peptides catalog.

Research Use Only

Mazdutide supplied by Pure Axis Peptides is intended strictly for laboratory and scientific research. It is not intended for human consumption, self-administration, diagnosis, treatment, cure, or prevention of any disease or medical condition. Mazdutide is a pharmacologically active GLP-1/glucagon receptor dual agonist, and regulatory approval in certain jurisdictions applies only to specified pharmaceutical products, formulations and indications. Clinical trial results should not be interpreted as establishing safety or efficacy for research-grade material or for self-directed use. Researchers should evaluate all materials according to their experimental requirements, product documentation and applicable laboratory procedures.

Internal Linking Recommendations

Primary Internal Links

• Semaglutide → https://pureaxispeptides.com/product/semaglutide/
• Tirzepatide → https://pureaxispeptides.com/product/tirzepatide/
• Survodutide → https://pureaxispeptides.com/product/survodutide/
• Retatrutide → https://pureaxispeptides.com/product/retatrutide/
• Cagrilintide → https://pureaxispeptides.com/product/cagrilintide/
• Peptides → https://pureaxispeptides.com/product-category/peptides/
• Shop All Products → https://pureaxispeptides.com/shop/

Verify all live WooCommerce URLs before publishing.

Recommended Internal-Link Anchors

Use varied contextual anchors such as:

• “Mazdutide research peptide”
• “Mazdutide research”
• “GLP-1/glucagon dual agonist”
• “Mazdutide metabolic research”
• “GLP-1 receptor research”
• “glucagon receptor research”
• “dual metabolic agonist research”
• “obesity research peptide”
• “liver-fat research”
• “MASLD research”
• “metabolic liver research”
• “GLP-1 and glucagon research”
• “multi-receptor metabolic peptide”

Recommended Site Architecture

Build a dedicated metabolic peptide cluster:

Mazdutide
→ GLP-1 receptor
→ Glucagon receptor
→ Dual agonism
→ Obesity
→ Type 2 diabetes
→ Energy metabolism
→ Liver fat
→ MASLD
→ Semaglutide
→ Tirzepatide
→ Survodutide
→ Retatrutide
→ Cagrilintide

A particularly strong supporting article would be:

“Mazdutide vs Semaglutide vs Tirzepatide vs Survodutide vs Retatrutide: Understanding Multi-Receptor Metabolic Peptides”

This gives you a central informational page capable of distributing internal authority across your entire metabolic-product cluster.

External Scientific References

• PubMed — Phase 3 Mazdutide obesity trial:
  Once-Weekly Mazdutide in Chinese Adults With Obesity or Overweight (pubmed.ncbi.nlm.nih.gov)
• PubMed — Mazdutide first approval:
  Mazdutide: First Approval (pubmed.ncbi.nlm.nih.gov)
• PubMed — High-dose Phase 1 Mazdutide trial:
  Mazdutide Reduces Body Weight in Adults With Overweight or Obesity (pubmed.ncbi.nlm.nih.gov)
• PubMed — Mazdutide 9 mg Phase 2 trial:
  Mazdutide 9 mg in Chinese Adults With Obesity (pubmed.ncbi.nlm.nih.gov)
• PubMed — Mazdutide vs Semaglutide Phase 3 trial design:
  DREAMS-3: Mazdutide Versus Semaglutide (pubmed.ncbi.nlm.nih.gov)

Product Tags

Mazdutide, Mazdutide Peptide, Mazdutide Research, Mazdutide Research Peptide, IBI362, IBI-362, Mazdutide IBI362, GLP-1 Glucagon Dual Agonist, GLP-1/Glucagon Agonist, GLP-1 Research, GLP-1 Peptide, GLP-1 Receptor, GLP-1R, Glucagon Research, Glucagon Receptor, GCGR, Dual Agonist Research, Metabolic Peptide, Metabolic Research, Obesity Research, Body Weight Research, Weight Regulation Research, Energy Metabolism, Energy Expenditure, Glucose Metabolism, Type 2 Diabetes Research, Glycemic Research, Insulin Sensitivity Research, Lipid Metabolism, Liver Research, Liver Fat Research, Hepatic Fat Research, MASLD Research, MASH Research, Metabolic Liver Disease, Body Composition Research, Visceral Adipose Research, Cardiometabolic Research, Multi-Receptor Peptide, Peptide Pharmacology, Research Peptide, Laboratory Research